Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
University of Toronto
$120,000.00
Uncovering female-specific regulation of lipid metabolism by GIP analogues through the brown adipose tissue
FY 2025-26
Summary
Obesity is a significant health risk with global projections estimating 21% of women will be living with the disease by 2025. Tirzepatide, the successor to semaglutide, is a medication that incorporates the use of the hormone: glucose dependent insulinotropic polypeptide (GIP). Due to the inclusion of GIP, this medication outperforms semaglutide in reducing body weight and regulating fat levels in the blood, which is thought to be partially due to the effects of GIP on fat tissue. This provides an incredible treatment option for individuals with obesity however, nearly all studies assessing the mechanisms of how GIP functions in fat tissue, excludes female models. My research has uncovered a novel finding where GIP improves fat clearance from the blood in male but not female mice. This male specific benefit of GIP treatment suggests that GIP may function differently in the fat tissue of females which has been overlooked due to the lack of the inclusion of female mouse models. This is an important consideration given that women are more likely than men to seek and receive pharmacological treatment for obesity.
To address this, my role will be to examine if long term dosing of GIP can enhance lipid uptake into female fat tissue, if retained insulin sensitivity overrides the beneficial effects of GIP in females, and determine if GIP is causing lipids to be stored in different tissues throughout the body compared to males. We will use mice without the receptor for GIP in the fat burning brown adipose tissue (BAT), so that GIP is no longer able to directly influence BAT to compare results between sexes and track the movement of fats. Understanding the role of GIP signalling in female BAT will reveal novel mechanisms of how GIP may function differently in females and help ensure that conclusions from males are not inappropriately generalized to females, supporting more precise care in the evolving field of women's health.
Department
Program
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
559681
Name
Lea Micah B
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Uncovering female-specific regulation of lipid metabolism by GIP analogues through the brown adipose tissue
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Brown Adipose Tissue; Diabetes; Glucose Dependent Insulinotropic Polypeptide; Incretin Hormone; Lipid Metabolism; Obesity; Physiology; Sex Based Differences
Abstract
Obesity is a significant health risk with global projections estimating 21% of women will be living with the disease by 2025. Tirzepatide, the successor to semaglutide, is a medication that incorporates the use of the hormone: glucose dependent insulinotropic polypeptide (GIP). Due to the inclusion of GIP, this medication outperforms semaglutide in reducing body weight and regulating fat levels in the blood, which is thought to be partially due to the effects of GIP on fat tissue. This provides an incredible treatment option for individuals with obesity however, nearly all studies assessing the mechanisms of how GIP functions in fat tissue, excludes female models. My research has uncovered a novel finding where GIP improves fat clearance from the blood in male but not female mice. This male specific benefit of GIP treatment suggests that GIP may function differently in the fat tissue of females which has been overlooked due to the lack of the inclusion of female mouse models. This is an important consideration given that women are more likely than men to seek and receive pharmacological treatment for obesity.
To address this, my role will be to examine if long term dosing of GIP can enhance lipid uptake into female fat tissue, if retained insulin sensitivity overrides the beneficial effects of GIP in females, and determine if GIP is causing lipids to be stored in different tissues throughout the body compared to males. We will use mice without the receptor for GIP in the fat burning brown adipose tissue (BAT), so that GIP is no longer able to directly influence BAT to compare results between sexes and track the movement of fats. Understanding the role of GIP signalling in female BAT will reveal novel mechanisms of how GIP may function differently in females and help ensure that conclusions from males are not inappropriately generalized to females, supporting more precise care in the evolving field of women's health.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lea, Micah B
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~